IL115663A - Pharmaceutical compositions containing benzothiophene derivatives for inhibiting physiological conditions associated with an excess of neuropeptide y - Google Patents
Pharmaceutical compositions containing benzothiophene derivatives for inhibiting physiological conditions associated with an excess of neuropeptide yInfo
- Publication number
- IL115663A IL115663A IL11566395A IL11566395A IL115663A IL 115663 A IL115663 A IL 115663A IL 11566395 A IL11566395 A IL 11566395A IL 11566395 A IL11566395 A IL 11566395A IL 115663 A IL115663 A IL 115663A
- Authority
- IL
- Israel
- Prior art keywords
- neuropeptide
- excess
- pharmaceutical compositions
- compositions containing
- physiological conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/326,675 US6562862B1 (en) | 1994-10-20 | 1994-10-20 | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
Publications (2)
Publication Number | Publication Date |
---|---|
IL115663A0 IL115663A0 (en) | 1996-01-19 |
IL115663A true IL115663A (en) | 1999-08-17 |
Family
ID=23273204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11566395A IL115663A (en) | 1994-10-20 | 1995-10-18 | Pharmaceutical compositions containing benzothiophene derivatives for inhibiting physiological conditions associated with an excess of neuropeptide y |
Country Status (19)
Country | Link |
---|---|
US (5) | US6562862B1 (zh) |
EP (1) | EP0785785A4 (zh) |
JP (1) | JPH10507757A (zh) |
KR (1) | KR970706818A (zh) |
CN (1) | CN1091598C (zh) |
AU (1) | AU689664B2 (zh) |
CA (1) | CA2200990A1 (zh) |
CZ (1) | CZ287411B6 (zh) |
FI (1) | FI971635A0 (zh) |
HU (1) | HUT76852A (zh) |
IL (1) | IL115663A (zh) |
MY (1) | MY132056A (zh) |
NO (1) | NO971520D0 (zh) |
NZ (1) | NZ295575A (zh) |
RU (1) | RU2188015C2 (zh) |
TW (1) | TW410156B (zh) |
UA (1) | UA46744C2 (zh) |
WO (1) | WO1996012490A1 (zh) |
ZA (1) | ZA958800B (zh) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
US5989920A (en) * | 1994-12-02 | 1999-11-23 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5 |
US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
US5494929A (en) * | 1995-01-12 | 1996-02-27 | Eli Lilly And Company | Methods of inhibiting growth hormone effects |
US5840747A (en) * | 1995-06-07 | 1998-11-24 | Eli Lilly And Company | Calcium channel antagonists |
US5532254A (en) * | 1995-06-07 | 1996-07-02 | Eli Lilly And Company | Modulation of calcium channels using benzothiophenes |
EP0759441A3 (en) * | 1995-06-30 | 1999-06-30 | Eli Lilly And Company | Methods of treating neuropeptide Y-associated conditions |
US5972624A (en) * | 1996-01-24 | 1999-10-26 | Synaptic Pharmaceutical Corporation | Method of identifying ligands which bind recombinant galanin receptor (GALR2) |
DE819167T1 (de) * | 1996-01-24 | 1998-04-09 | Synaptic Pharma Corp | Dns codierend für galanin galr2 rezeptoren und deren verwendung |
US6113876A (en) * | 1996-01-29 | 2000-09-05 | Eli Lilly And Company | Methods of increasing sphincter competence |
EP0910378A4 (en) * | 1996-01-29 | 1999-06-23 | Lilly Co Eli | METHODS FOR INCREASING THE EFFICIENCY OF SPHINCTERS |
DK0984778T3 (da) | 1996-08-23 | 2002-09-16 | Agouron Pharma | Neuropeptid-Y-ligander |
US6329197B2 (en) | 1996-10-09 | 2001-12-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
FR2754709B1 (fr) | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
US5900418A (en) * | 1997-02-10 | 1999-05-04 | Synapse Pharmaceuticals International, Inc. | Method for treatment of obesity |
US6048900A (en) | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
EP0927166A1 (en) * | 1997-02-14 | 1999-07-07 | Bayer Corporation | Amides as npy5 receptor antagonists |
WO1998035957A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
US6245817B1 (en) | 1997-02-14 | 2001-06-12 | Bayer Corporation | NPY5 receptor antagonists and methods for using same |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
WO1998047505A1 (fr) * | 1997-04-23 | 1998-10-29 | Banyu Pharmaceutical Co., Ltd. | Antagoniste de recepteur de neuropeptide y |
US6713265B1 (en) | 1997-06-04 | 2004-03-30 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
ATE234098T1 (de) * | 1997-08-05 | 2003-03-15 | Pfizer Prod Inc | 4-aminopyrrole (3,2-d) pyrimidinen als antagonisten des neuropeptide y receptors |
IL133430A0 (en) | 1997-08-05 | 2001-04-30 | Pfizer Prod Inc | 4-AMINOPYRROLE (3, 2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
US6008232A (en) * | 1997-08-20 | 1999-12-28 | Eli Lilly And Company | Methods for preventing headaches |
AU9105598A (en) * | 1997-08-21 | 1999-03-08 | Eli Lilly And Company | Methods for inhibiting fibrous inflammatory disease and riedel's thyroiditis |
AU9106198A (en) * | 1997-08-21 | 1999-03-08 | Eli Lilly And Company | Methods for inhibiting temporomandibular disorders |
US5990129A (en) * | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
US20050107327A1 (en) * | 1997-12-19 | 2005-05-19 | Hormos Medical Corporation | Method for reducing overproduction of neuropeptide Y in an individual |
US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
GB2344050A (en) * | 1998-11-26 | 2000-05-31 | Ferring Bv | Agents useful in the treatment of reproductive disorders. |
PT1027891E (pt) | 1999-01-27 | 2005-04-29 | Pfizer Prod Inc | Antagonista de neuropeptido y |
KR20010101931A (ko) * | 1999-02-03 | 2001-11-15 | 피터 지. 스트링거 | α1-아드레날린성 수용체 길항제 |
DE19905961A1 (de) * | 1999-02-12 | 2000-08-17 | Stefan Neubauer | Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz |
AU3511500A (en) * | 1999-03-05 | 2000-09-21 | Trustees Of University Technology Corporation, The | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions |
AU2935200A (en) | 1999-04-30 | 2000-11-17 | Pfizer Products Inc. | Compounds for the treatment of obesity |
ATE318267T1 (de) | 1999-09-30 | 2006-03-15 | Neurogen Corp | Einige alkylendiamin-substituierte heterocyclen |
WO2001026651A2 (en) * | 1999-10-14 | 2001-04-19 | Endorecherche, Inc. | Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance |
AU2001232900A1 (en) * | 2000-01-20 | 2001-07-31 | Michael Amling | Methods and compositions for control of bone formation via modulation of neuropeptide y activity |
JP2001261674A (ja) * | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
US6511984B2 (en) | 2000-03-30 | 2003-01-28 | Pfizer Inc. | Neuropeptide Y antagonists |
US20020061897A1 (en) | 2000-03-30 | 2002-05-23 | Elliott Richard L. | Neuropeptide Y antagonists |
US6358991B2 (en) | 2000-07-06 | 2002-03-19 | American Home Products Corporation | Methods of treating neuropeptide Y-related conditions |
TWI303990B (en) * | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
IL162269A0 (en) | 2001-12-05 | 2005-11-20 | Baylor College Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
US6958347B2 (en) * | 2002-12-18 | 2005-10-25 | Pfizer Inc. | Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists |
US6949564B2 (en) * | 2002-12-18 | 2005-09-27 | Pfizer Inc. | NPY-5 antagonists |
JP2004224756A (ja) * | 2003-01-24 | 2004-08-12 | Sumika Fine Chemicals Co Ltd | 2,6−ジハロゲノ−8−置換−プリン化合物およびその製造方法 |
US20040220242A1 (en) * | 2003-05-02 | 2004-11-04 | Leland Shapiro | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions |
ATE462432T1 (de) | 2003-05-05 | 2010-04-15 | Probiodrug Ag | Glutaminylcyclase-hemmer |
ES2228268B1 (es) * | 2003-07-30 | 2006-07-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6. |
NZ546887A (en) | 2003-11-03 | 2009-04-30 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
AU2005210004B2 (en) | 2004-02-05 | 2010-10-28 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
US8642079B2 (en) * | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US8758821B2 (en) * | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
BRPI0510465B8 (pt) | 2004-05-04 | 2021-05-25 | Hormos Medical Ltd | formulação de droga oral líquida em forma de solução e formulação de droga oral líquida ou semi-sólida |
CA2588087A1 (en) * | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
WO2006108218A1 (en) * | 2005-04-15 | 2006-10-19 | Regenertech Pty Limited | Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
EP2518039B8 (en) * | 2007-02-14 | 2014-12-17 | Forendo Pharma Ltd. | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
WO2008099060A2 (en) * | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
WO2009071601A1 (en) | 2007-12-03 | 2009-06-11 | Obe Therapy Biotechnology | Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism |
ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
EP2545047B9 (en) | 2010-03-10 | 2015-06-10 | Probiodrug AG | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
US9321712B2 (en) | 2012-10-19 | 2016-04-26 | Fermion Oy | Process for the preparation of ospemifene |
ES2671516T3 (es) * | 2013-02-19 | 2018-06-06 | Novartis Ag | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4891357A (en) * | 1985-02-11 | 1990-01-02 | University Of Florida | Methods and compositions for stimulation of appetite |
US5075321A (en) | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
JP3157882B2 (ja) | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
JPH07502268A (ja) | 1991-11-27 | 1995-03-09 | ノボ ノルディスク アクティーゼルスカブ | 化学化合物、それらの製法および使用 |
TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
TW383306B (en) | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
US5482949A (en) | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
DE4311870C2 (de) | 1993-04-10 | 1998-07-30 | Altramed Holdings Ltd | Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen |
US5445941A (en) | 1993-06-21 | 1995-08-29 | Eli Lilly And Company | Method for screening anti-osteoporosis agents |
ZA944377B (en) | 1993-06-24 | 1995-12-20 | Lilly Co Eli | Hypoglycemic agents |
TW303299B (zh) | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
US5468773A (en) | 1993-08-25 | 1995-11-21 | Eli Lilly And Company | Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs |
US5457113A (en) | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell proliferation and restinosis |
RU94044323A (ru) | 1993-12-21 | 1996-11-10 | Эли Лилли энд Компани (US) | Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления |
US5441965A (en) | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
US5578613A (en) | 1993-12-21 | 1996-11-26 | Eli Lilly And Company | Methods for inhibiting weight gain or inducing weight loss |
US6417198B1 (en) * | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
US5447941A (en) * | 1993-12-21 | 1995-09-05 | Eli Lilly And Company | Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes |
US5439931A (en) * | 1993-12-21 | 1995-08-08 | Eli Lilly And Company | Method for increasing libido in post-menopausal women |
US5476862A (en) | 1993-12-21 | 1995-12-19 | Eli Lilly And Company | Methods of increasing thrombomodulin expression |
US5574047A (en) | 1993-12-21 | 1996-11-12 | Eli Lilly And Company | Methods of inhibiting imperfect tissue repair |
US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
-
1994
- 1994-10-20 US US08/326,675 patent/US6562862B1/en not_active Expired - Fee Related
-
1995
- 1995-08-21 US US08/517,303 patent/US5504094A/en not_active Expired - Fee Related
- 1995-08-21 US US08/517,315 patent/US5567715A/en not_active Expired - Fee Related
- 1995-08-21 US US08/517,316 patent/US5576337A/en not_active Expired - Fee Related
- 1995-08-21 US US08/517,049 patent/US5567714A/en not_active Expired - Fee Related
- 1995-10-18 IL IL11566395A patent/IL115663A/xx not_active IP Right Cessation
- 1995-10-18 TW TW084110967A patent/TW410156B/zh not_active IP Right Cessation
- 1995-10-18 ZA ZA958800A patent/ZA958800B/xx unknown
- 1995-10-19 AU AU38955/95A patent/AU689664B2/en not_active Ceased
- 1995-10-19 CN CN95195703A patent/CN1091598C/zh not_active Expired - Fee Related
- 1995-10-19 CZ CZ19971159A patent/CZ287411B6/cs not_active IP Right Cessation
- 1995-10-19 WO PCT/US1995/013246 patent/WO1996012490A1/en not_active Application Discontinuation
- 1995-10-19 UA UA97041869A patent/UA46744C2/uk unknown
- 1995-10-19 RU RU97108050/14A patent/RU2188015C2/ru active
- 1995-10-19 MY MYPI95003138A patent/MY132056A/en unknown
- 1995-10-19 HU HU9701520A patent/HUT76852A/hu unknown
- 1995-10-19 JP JP8514008A patent/JPH10507757A/ja active Pending
- 1995-10-19 KR KR1019970702591A patent/KR970706818A/ko not_active Application Discontinuation
- 1995-10-19 EP EP95938248A patent/EP0785785A4/en not_active Withdrawn
- 1995-10-19 CA CA002200990A patent/CA2200990A1/en not_active Abandoned
-
1997
- 1997-04-03 NO NO971520A patent/NO971520D0/no not_active Application Discontinuation
- 1997-04-17 FI FI971635A patent/FI971635A0/fi unknown
- 1997-04-17 NZ NZ295575A patent/NZ295575A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1996012490A1 (en) | 1996-05-02 |
US5567714A (en) | 1996-10-22 |
RU2188015C2 (ru) | 2002-08-27 |
EP0785785A4 (en) | 1998-11-11 |
US5576337A (en) | 1996-11-19 |
AU689664B2 (en) | 1998-04-02 |
TW410156B (en) | 2000-11-01 |
MY132056A (en) | 2007-09-28 |
CN1091598C (zh) | 2002-10-02 |
NZ295575A (en) | 2000-06-23 |
US6562862B1 (en) | 2003-05-13 |
IL115663A0 (en) | 1996-01-19 |
JPH10507757A (ja) | 1998-07-28 |
UA46744C2 (uk) | 2002-06-17 |
FI971635A (fi) | 1997-04-17 |
CA2200990A1 (en) | 1996-05-02 |
EP0785785A1 (en) | 1997-07-30 |
NO971520L (no) | 1997-04-03 |
AU3895595A (en) | 1996-05-15 |
MX9702853A (es) | 1997-07-31 |
CZ115997A3 (en) | 1997-10-15 |
CZ287411B6 (en) | 2000-11-15 |
CN1160998A (zh) | 1997-10-01 |
US5567715A (en) | 1996-10-22 |
FI971635A0 (fi) | 1997-04-17 |
ZA958800B (en) | 1997-04-18 |
HUT76852A (en) | 1997-12-29 |
NO971520D0 (no) | 1997-04-03 |
KR970706818A (ko) | 1997-12-01 |
US5504094A (en) | 1996-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL115663A (en) | Pharmaceutical compositions containing benzothiophene derivatives for inhibiting physiological conditions associated with an excess of neuropeptide y | |
IL116957A0 (en) | Substituted heterocyclic compounds their preparation and pharmaceutical compositions containing them | |
HUT72888A (en) | Pharmaceutical compositions comprising carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation | |
ZA925573B (en) | 5-membered heterocyclic compounds processes for preparing them and pharmaceutical compositions containing these compounds | |
HU9800291D0 (en) | Use of amido-pirimidine derivatives for producing pharmaceutical compositions for inhibiting decrease of glucose-metabolismus | |
ZA987552B (en) | Pharmaceutical composition for combination of piperidino-alkanol-decongestant | |
IL111314A (en) | Pharmaceutical compositions containing indole derivatives | |
IL119778A (en) | Neuropretective pharmaceutical compositions containing rapamycin derivatives | |
IL98239A0 (en) | Benzopyran derivatives and heterocyclic analogs thereof and pharmaceutical compositions containing the same | |
NZ224347A (en) | Heterocyclic compounds and pharmaceutical compositions | |
IL123095A0 (en) | Pharmaceutical compositions containing fluconazole for inhibiting the growth of cancers | |
IL117620A0 (en) | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same | |
PL330904A1 (en) | Novel derivative of thiophene and pharmaceutic composition containing such derivative | |
PL326033A1 (en) | Heteroaryl-substituted derivatives of acrylolguanidine and pharmaceutic compositions containing them | |
IL114534A (en) | Heterocyclic derivatives of azolones their preparation and pharmaceutical compositions containing them | |
HU9302491D0 (en) | Neolignane derivatives and pharmaceutical compositions containing them | |
IL106385A0 (en) | Heterocyclic compounds,their preparation and pharmaceutical compositions containing them | |
ZA9710919B (en) | Pharmaceutical compositions containing N-sulphony-lindole derivatives | |
IL115614A (en) | Pharmaceutical compositions containing benzothiophene derivatives for inhibiting physiological conditions associated with an excess of bradykinin | |
IL104417A0 (en) | Substituted dihydroindene and-acenaphthene derivatives and pharmaceutical compositions containing them | |
IL106041A0 (en) | Heterocyclic compounds,their preparation and pharmaceutical compositions containing them | |
HUP0001061A3 (en) | Naphthylsulfonic acid derivatives and pharmaceutical compositions containing them | |
IL98405A0 (en) | Pharmaceutical compositions containing enzyme inhibiting agents | |
IL123424A0 (en) | Heterocyclic compounds their preparation and pharmaceutical compositions containing them | |
HUP9801829A3 (en) | Use of benzotiophene derivatives for producing pharmaceutical compositions for inhibiting effects of il-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |